ArticleClinical & experimental metastasis2026
Predictive significance of anterior and posterior minimal extrathyroidal extension for central lymph node metastasis in cN0 papillary thyroid carcinoma.
Article in Clinical & experimental metastasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The specific role of minimal extrathyroidal extension (mETE)-particularly the differences between anterior mETE (ant-mETE) and posterior mETE (post-mETE)-in relation to Central lymph node metastasis (CLNM) for papillary thyroid carcinoma (PTC) remains uncertain. This study aimed to examine the effects of ant-mETE and post-mETE on CLNM and to construct a preoperative risk-stratification nomogram for CLNM to guide central lymph node dissection (CLND). This retrospective study analyzed 1694 consecutive clinically node-negative (cN0) PTC cases treated between 2017 and 2024. Univariate and multivariate analyses were performed to identify clinicopathological predictors of CLNM. Subsequently, a predictive nomogram incorporating significant variables was developed and internally validated. Among 1694 cN0 PTC cases analyzed, 833 (49.2%) demonstrated pathologic CLNM, and post-mETE was significantly associated with higher CLNM rates compared to ant-mETE (p < 0.001). Multivariable analysis identified seven independent CLNM predictors: age > 55 years (OR 0.466), male gender (OR 2.479), tumor size > 1 cm (OR 3.290), bilateral involvement (OR 1.335), multifocality (OR 1.420), lower pole location (OR 1.710), and mETE presence (ant-mETE OR = 2.47, post-mETE OR = 3.492). The developed nomogram demonstrated excellent discriminative ability (AUC = 0.774) and clinical utility. Both ant-mETE and post-mETE were independently associated with CLNM, with post-mETE demonstrating significantly higher metastatic propensity. The predictive nomogram developed in this study demonstrated moderate discriminative accuracy for CLNM, which could help identify occult metastases, thereby facilitating prophylactic CLND and reducing reoperation rates in patients.
Indexed as
Identifiers
41511663What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.